As of November 6, 2026, Cero Therapeutics Holdings, Inc. has Schedule 13D or 13G filings on record, none whose latest reports a stake of 5% or more. 3 filings are on record since August 14, 2025 (Schedule 13G/A, August 14, 2026).
Sell to companies like Cero Therapeutics Holdings, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Tibbs Isaiah · Sole voting: 2,089,000 · Shared voting: 0 · Sole dispositive: 2,089,000 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-08-14
- · Holder: Tibbs Isaiah · Percent: 8.67% · SCHEDULE 13G
- · Holder: Armistice Capital, LLC · Percent: 4.99% · SCHEDULE 13G/A
Cero Therapeutics Holdings, Inc. has 3 Schedule 13D or 13G filings on record since 2025-08-14. No holder's latest filing reports 5% or more. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Armistice Capital, LLC | 4.99% | 63,308 | SCHEDULE 13G/A, 2025-08-14 | 2025-06-30 |
| 4.63% | 2,089,000 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
Holding shares or following this stake? See who's behind Cero Therapeutics Holdings, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Cero Therapeutics Holdings, Inc. and the records around it.
Cero Therapeutics Holdings, Inc. elsewhere on the record
- IPO filing Dec 2025
- Form D filing May 2025
Companies that share a holder
- Armistice Capital, LLC also filed stake reports on 120 other companies: Autolus Therapeutics plc (Aug 2026), Bicycle Therapeutics plc (Aug 2026), BioXcel Therapeutics, Inc. (Aug 2026)
Watch Cero Therapeutics Holdings, Inc.
Get an email when Cero Therapeutics Holdings, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Cero Therapeutics Holdings, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Cero Therapeutics Holdings, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Cero Therapeutics Holdings, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Tibbs Isaiah | 2,089,000 | 0 | 2,089,000 | 0 | SCHEDULE 13G/A, 2026-08-14 |
The latest filing identifies Cero Therapeutics Holdings, Inc. by CUSIP 15687V102 and gives its principal executive office as 201 HASKINS WAY, SUITE 230, SOUTH SAN FRANCISCO, CA 94080 (SCHEDULE 13G/A, 2026-08-14).
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-14 | Armistice Capital, LLC | 4.99% | SCHEDULE 13G/A |
| 2026-03-12 | Tibbs Isaiah | 8.67% | SCHEDULE 13G |
| 2026-08-14 | Tibbs Isaiah | 4.63% | SCHEDULE 13G/A |
Also on the record for Cero Therapeutics Holdings, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| December 5, 2025 | IPO filing, Form S-1 | — | IPO filings | Source |
| July 21, 2025 | IPO filing, Form S-1 | — | IPO filings | Source |
| May 6, 2025 | Form D, private offering | $5M sold | Form D page | Source |
| February 5, 2025 | IPO filing, Form S-1/A | — | IPO filings | Source |
| January 21, 2025 | IPO filing, Form S-1/A | — | IPO filings | Source |
| December 23, 2024 | IPO filing, Form S-1 | — | IPO filings | Source |
| November 27, 2024 | IPO filing, Form S-1 | — | IPO filings | Source |
| November 25, 2024 | IPO filing, Form S-1/A | — | IPO filings | Source |
| October 22, 2024 | IPO filing, Form S-1/A | — | IPO filings | Source |
| October 21, 2024 | IPO filing, Form S-1 | — | IPO filings | Source |
Tools for this story
Each opens in a new tab, filled in for Cero Therapeutics Holdings, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.